4142:TPE
Adimmune Corp
NT$17,80
arrow_downward
-0,56%(-0,10) 1 HR
22 Okt, 13.30.07 GMT+8 · TWD
search
Semua simbol
| Simbol | Harga | Perubahan | Persentase Perubahan |
|---|
insights_autoMembuat insight teratas untuk 4142...
Pembukaan
NT$17,90
Tinggi
NT$17,95
Rendah
NT$17,75
Kapitalisasi pasar
7,65 M
Volume rata-rata
1,06 jt
Volume
328,73 rb
Harga tinggi dalam 52 minggu terakhir
NT$22,50
Harga rendah dalam 52 minggu terakhir
NT$16,40
EPS
-NT$0,34
Saham beredar
235,29 jt
Jumlah karyawan
564
Pembukaan
NT$17,90
Tinggi
NT$17,95
Rendah
NT$17,75
Kapitalisasi pasar
7,65 M
Volume rata-rata
1,06 jt
Volume
328,73 rb
Harga tinggi dalam 52 minggu terakhir
NT$22,50
Harga rendah dalam 52 minggu terakhir
NT$16,40
EPS
-NT$0,34
Saham beredar
235,29 jt
Jumlah karyawan
564
Artikel berita
Dari sumber web dan partner berita
شبكة تواصل الإخبارية
·
1 hari yang lalu
S&P 500: Guncangan AI dan energi membebani ekuitas – Deutsche Bank
KabarBursa.com
·
12 jam yang lalu
Dow Kehilangan 652,82 Poin, Wall Street Amblas di Tengah Tekanan AI
Kompas.com
·
4 jam yang lalu
Wall Street Tertekan, Dow Jones Anjlok 652 Poin Saat Harga Minyak Naik
MetroTVNews.com
·
11 jam yang lalu
Wall Street Ditutup Melemah, Dow Jones Ambruk hingga 1,23%
Profil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Tentang Adimmune Corp